Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice

[1]  M. Adzic,et al.  Alterations in the Nrf2–Keap1 signaling pathway and its downstream target genes in rat brain under stress , 2015, Brain Research.

[2]  Zhihui Feng,et al.  Maternal hydroxytyrosol administration improves neurogenesis and cognitive function in prenatally stressed offspring. , 2015, The Journal of nutritional biochemistry.

[3]  A. Rodrigues,et al.  Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice , 2014, Pharmacology Biochemistry and Behavior.

[4]  A. Verkhratsky,et al.  Astrogliopathology: a central element of neuropsychiatric diseases? , 2014, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[5]  Kerri Smith,et al.  Mental health: A world of depression , 2014, Nature.

[6]  Andiara E. Freitas,et al.  Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice. , 2014, Journal of psychiatric research.

[7]  N. J. Allen,et al.  Astrocyte regulation of synaptic behavior. , 2014, Annual review of cell and developmental biology.

[8]  I. Soldatovic,et al.  Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients , 2014, Neuropsychobiology.

[9]  S. Maier,et al.  Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis , 2014, Molecular Psychiatry.

[10]  Hong Wang,et al.  Aquaporin‐4 Knockout Exacerbates Corticosterone‐Induced Depression by Inhibiting Astrocyte Function and Hippocampal Neurogenesis , 2014, CNS neuroscience & therapeutics.

[11]  Andiara E. Freitas,et al.  Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  J. Herman,et al.  Glucocorticoid actions on synapses, circuits, and behavior: Implications for the energetics of stress , 2014, Frontiers in Neuroendocrinology.

[13]  Andiara E. Freitas,et al.  Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration , 2014, Behavioural Brain Research.

[14]  Dominique Muller,et al.  Astrocyte-Synapse Structural Plasticity , 2014, Neural plasticity.

[15]  P. Rada,et al.  Agmatine Induces Nrf2 and Protects Against Corticosterone Effects in Hippocampal Neuronal Cell Line , 2014, Molecular Neurobiology.

[16]  Andiara E. Freitas,et al.  NMDA receptors and the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice. , 2013, Journal of medicinal food.

[17]  M. Śmiałowska,et al.  Glial degeneration as a model of depression , 2013, Pharmacological reports : PR.

[18]  A. Roman,et al.  Macrophages and depression — A misalliance or well-arranged marriage? , 2013, Pharmacological reports : PR.

[19]  Antonio Cuadrado,et al.  Nrf2 participates in depressive disorders through an anti-inflammatory mechanism , 2013, Psychoneuroendocrinology.

[20]  P. Masand,et al.  Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  G. Rajkowska,et al.  Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. , 2013, Current drug targets.

[22]  B. Czéh,et al.  Altered glial plasticity in animal models for mood disorders. , 2013, Current drug targets.

[23]  N. Maric,et al.  Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. , 2013, Psychiatria Danubina.

[24]  J. Piletz,et al.  Agmatine: clinical applications after 100 years in translation. , 2013, Drug discovery today.

[25]  M. Banasr,et al.  From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders , 2013, Biological Psychiatry.

[26]  T. Frodl,et al.  How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans , 2013, Neurobiology of Disease.

[27]  B. Shopsin.  The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study , 2013, Acta Neuropsychiatrica.

[28]  K. Turpaev.  Keap1-Nrf2 signaling pathway: Mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles , 2013, Biochemistry (Moscow).

[29]  Andiara E. Freitas,et al.  Antidepressant-like action of the bark ethanolic extract from Tabebuia avellanedae in the olfactory bulbectomized mice. , 2013, Journal of ethnopharmacology.

[30]  K. Turpaev.  Keap1-Nrf2 signaling pathway: Mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles , 2013, Biochemistry (Moscow).

[31]  H. Onoe,et al.  Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice , 2013, Neuropharmacology.

[32]  Andiara E. Freitas,et al.  Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice , 2013, Behavioural Brain Research.

[33]  M. Maes,et al.  Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression , 2012, Neuroscience & Biobehavioral Reviews.

[34]  Zhen Yan,et al.  The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission , 2011, Nature Reviews Neuroscience.

[35]  M. Berk,et al.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors , 2012, Inflammopharmacology.

[36]  P. Liu,et al.  Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals , 2011, Neuroscience.

[37]  Antonia Garrido Frenich,et al.  Development and validation of an ultra-high performance liquid chromatography–tandem mass-spectrometry (UHPLC–MS/MS) method for the simultaneous determination of neurotransmitters in rat brain samples , 2011, Journal of Neuroscience Methods.

[38]  A. Lussier,et al.  Reelin as a putative vulnerability factor for depression: Examining the depressogenic effects of repeated corticosterone in heterozygous reeler mice , 2011, Neuropharmacology.

[39]  R. Choi,et al.  The establishment of a sensitive method in determining different neurotransmitters simultaneously in rat brains by using liquid chromatography-electrospray tandem mass spectrometry. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[40]  Jun Ma,et al.  Fates-shifted, a novel F-box protein that targets Bicoid for degradation, regulates developmental fate determination in Drosophila embryos , 2010, Nature Cell Biology.

[41]  B. Lu,et al.  New Insights in the Biology of BDNF Synthesis and Release: Implications in CNS Function , 2009, The Journal of Neuroscience.

[42]  V. Camus,et al.  Association between Repeated Unpredictable Chronic Mild Stress (UCMS) Procedures with a High Fat Diet: A Model of Fluoxetine Resistance in Mice , 2010, PloS one.

[43]  Andiara E. Freitas,et al.  Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: Evidence for the involvement of the monoaminergic system , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  B. Anderson,et al.  The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: Implications for hippocampal volume reductions in depression , 2010, Physiology & Behavior.

[45]  K. Thomas,et al.  A Simple Role for BDNF in Learning and Memory? , 2009, Front. Mol. Neurosci..

[46]  B. Taksande,et al.  Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine , 2009, Neuropharmacology.

[47]  C. Hammen,et al.  Chronic and acute stress and the prediction of major depression in women , 2009, Depression and anxiety.

[48]  A. Papadimitriou,et al.  Regulation of the Hypothalamic-Pituitary-Adrenal Axis , 2009, Neuroimmunomodulation.

[49]  R. Zhu,et al.  Determination of 5-Hydroxytryptamine, Norepinephrine, Dopamine and Their Metabolites in Rat Brain Tissue by LC–ESI–MS–MS , 2009 .

[50]  G. MacQueen,et al.  A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. , 2009, Journal of psychiatry & neuroscience : JPN.

[51]  M. Maj,et al.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression , 2009, Metabolic Brain Disease.

[52]  DelindaA . Johnson,et al.  The Nrf2–ARE Pathway , 2008, Annals of the New York Academy of Sciences.

[53]  Stafford L. Lightman,et al.  The HPA axis in major depression: classical theories and new developments , 2008, Trends in Neurosciences.

[54]  Ji Li,et al.  [5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine]. , 2008, Yao xue xue bao = Acta pharmaceutica Sinica.

[55]  G. Ordway,et al.  Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain. , 2008, The European journal of neuroscience.

[56]  A. Marini,et al.  Brain‐Derived Neurotrophic Factor in Neuronal Survival and Behavior‐Related Plasticity , 2007, Annals of the New York Academy of Sciences.

[57]  L. Stone,et al.  Potassium‐ and capsaicin‐induced release of agmatine from spinal nerve terminals , 2007, Journal of neurochemistry.

[58]  G. Bissette,et al.  Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons , 2006, Neuroscience.

[59]  A. Rodrigues,et al.  Contribution of spinal glutamatergic receptors to the antinociception caused by agmatine in mice , 2006, Brain Research.

[60]  Wei-Ping Wang,et al.  Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons , 2006, Brain Research.

[61]  Jiankun Cui,et al.  Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[62]  James P. Herman,et al.  Limbic system mechanisms of stress regulation: Hypothalamo-pituitary-adrenocortical axis , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[63]  A. Rodrigues,et al.  Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test , 2005, Neuroscience Letters.

[64]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[65]  A. Rodrigues,et al.  Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test , 2004, Brain Research.

[66]  R. Duman.  Neural plasticity: consequences of stress and actions of antidepressant treatment , 2004, Dialogues in clinical neuroscience.

[67]  A. Jaiswal,et al.  Nrf2 signaling in coordinated activation of antioxidant gene expression. , 2004, Free radical biology & medicine.

[68]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[69]  Y. Surh,et al.  Cancer chemoprevention with dietary phytochemicals , 2003, Nature Reviews Cancer.

[70]  Angela L. Lee,et al.  Stress and depression: possible links to neuron death in the hippocampus. , 2002, Bipolar disorders.

[71]  A. Rodrigues,et al.  Agmatine produces antidepressant-like effects in two models of depression in mice , 2002, Neuroreport.

[72]  M. Wong,et al.  Research and treatment approaches to depression , 2001, Nature Reviews Neuroscience.

[73]  D. Reis,et al.  Is agmatine a novel neurotransmitter in brain? , 2000, Trends in pharmacological sciences.

[74]  G. Olmos,et al.  Protection by imidazol(ine) drugs and agmatine of glutamate‐induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor , 1999, British journal of pharmacology.

[75]  D. Reis,et al.  Agmatine: An Endogenous Ligand at Imidazoline Receptors Is a Novel Neurotransmitter a , 1999, Annals of the New York Academy of Sciences.

[76]  D. Reis,et al.  Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. , 1998, Journal of the autonomic nervous system.

[77]  K. Itoh,et al.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. , 1997, Biochemical and biophysical research communications.

[78]  D. Souza,et al.  Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. , 1996, Pharmacology & toxicology.

[79]  J. Rabey,et al.  Agmatine treatment is neuroprotective in rodent brain injury models. , 1995, Life sciences.

[80]  P. Plotsky,et al.  Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: studies on the adrenocorticotropin response to ether stress and exogenous CRF. , 1984, Endocrinology.

[81]  J. Mendels,et al.  Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. , 1976, Archives of general psychiatry.